JPH11512623A - 多発性硬化症モデルとしての非−遺伝子修飾哺乳類 - Google Patents
多発性硬化症モデルとしての非−遺伝子修飾哺乳類Info
- Publication number
- JPH11512623A JPH11512623A JP9532343A JP53234397A JPH11512623A JP H11512623 A JPH11512623 A JP H11512623A JP 9532343 A JP9532343 A JP 9532343A JP 53234397 A JP53234397 A JP 53234397A JP H11512623 A JPH11512623 A JP H11512623A
- Authority
- JP
- Japan
- Prior art keywords
- glial
- animal
- cells
- brain
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000124008 Mammalia Species 0.000 title claims abstract description 8
- 201000006417 multiple sclerosis Diseases 0.000 title claims description 63
- 241001465754 Metazoa Species 0.000 claims abstract description 82
- 210000004556 brain Anatomy 0.000 claims abstract description 21
- 239000008280 blood Substances 0.000 claims abstract description 20
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 15
- 230000002025 microglial effect Effects 0.000 claims abstract description 12
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 11
- 210000000133 brain stem Anatomy 0.000 claims abstract description 9
- 230000005856 abnormality Effects 0.000 claims abstract description 8
- 210000004885 white matter Anatomy 0.000 claims abstract description 8
- 210000004498 neuroglial cell Anatomy 0.000 claims abstract description 7
- 230000003140 astrocytic effect Effects 0.000 claims abstract description 6
- 230000020411 cell activation Effects 0.000 claims abstract description 3
- 230000005779 cell damage Effects 0.000 claims abstract description 3
- 208000037887 cell injury Diseases 0.000 claims abstract description 3
- 230000004888 barrier function Effects 0.000 claims abstract 2
- 230000002518 glial effect Effects 0.000 claims description 58
- 210000001130 astrocyte Anatomy 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 41
- 230000002588 toxic effect Effects 0.000 claims description 36
- 231100000331 toxic Toxicity 0.000 claims description 34
- 239000000304 virulence factor Substances 0.000 claims description 23
- 230000007923 virulence factor Effects 0.000 claims description 23
- 230000001225 therapeutic effect Effects 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 230000001575 pathological effect Effects 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 239000013060 biological fluid Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 230000003210 demyelinating effect Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 230000004660 morphological change Effects 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 abstract description 10
- 206010018341 Gliosis Diseases 0.000 abstract description 5
- 230000007387 gliosis Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 80
- 241000700159 Rattus Species 0.000 description 41
- 239000002609 medium Substances 0.000 description 20
- 230000008499 blood brain barrier function Effects 0.000 description 19
- 210000001218 blood-brain barrier Anatomy 0.000 description 19
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 19
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 18
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 18
- 230000003902 lesion Effects 0.000 description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 239000003053 toxin Substances 0.000 description 12
- 231100000765 toxin Toxicity 0.000 description 12
- 108700012359 toxins Proteins 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 11
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 10
- 230000001086 cytosolic effect Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 208000016192 Demyelinating disease Diseases 0.000 description 9
- 206010012305 Demyelination Diseases 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 229920001917 Ficoll Polymers 0.000 description 7
- 102000006386 Myelin Proteins Human genes 0.000 description 7
- 108010083674 Myelin Proteins Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000005012 myelin Anatomy 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000001638 cerebellum Anatomy 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 210000000274 microglia Anatomy 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000001577 neostriatum Anatomy 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 239000012979 RPMI medium Substances 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004958 brain cell Anatomy 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100026735 Coagulation factor VIII Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000000576 arachnoid Anatomy 0.000 description 3
- 208000037875 astrocytosis Diseases 0.000 description 3
- 230000007341 astrogliosis Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 102100026044 Biotinidase Human genes 0.000 description 2
- 108010039206 Biotinidase Proteins 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 241000272184 Falconiformes Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000002330 subarachnoid space Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000272185 Falco Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 108010045198 H-2 Antigens Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NIPLIJLVGZCKMP-UHFFFAOYSA-M Neurine Chemical compound [OH-].C[N+](C)(C)C=C NIPLIJLVGZCKMP-UHFFFAOYSA-M 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000042032 Petrocephalus catostoma Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002502 anti-myelin effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Rheumatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR96/03417 | 1996-03-14 | ||
| FR9603417A FR2745974B1 (fr) | 1996-03-14 | 1996-03-14 | Animal modifie, utilisations et procede pour mesurer l'efficacite d'un procede therapeutique |
| PCT/FR1997/000469 WO1997033466A1 (fr) | 1996-03-14 | 1997-03-14 | Mammifere non genetiquement modifie, modele pour la sclerose en plaques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH11512623A true JPH11512623A (ja) | 1999-11-02 |
Family
ID=9490322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9532343A Pending JPH11512623A (ja) | 1996-03-14 | 1997-03-14 | 多発性硬化症モデルとしての非−遺伝子修飾哺乳類 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0825811A1 (fr) |
| JP (1) | JPH11512623A (fr) |
| AU (1) | AU2165897A (fr) |
| CA (1) | CA2221028A1 (fr) |
| FR (1) | FR2745974B1 (fr) |
| WO (1) | WO1997033466A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2797402B1 (fr) | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune |
| WO2005067708A2 (fr) * | 2004-01-14 | 2005-07-28 | Daniolabs Limited | Modeles d'animaux et utilisations de ceux-ci |
| WO2016022387A2 (fr) * | 2014-08-07 | 2016-02-11 | Tisch Multiple Sclerosis Research Center Of New York | Modèle de souris pour sclérose en plaques |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2716198B1 (fr) * | 1994-02-15 | 1996-04-19 | Bio Merieux | Facteur cytotoxique tel qu'associé à la sclérose en plaques, sa détection et sa quantification. |
| EP0685558A1 (fr) * | 1994-05-27 | 1995-12-06 | Bayer Ag | Animaux transgéniques déficients en protéine protéolipidique et méthode d'obtention de tels animaux |
-
1996
- 1996-03-14 FR FR9603417A patent/FR2745974B1/fr not_active Expired - Fee Related
-
1997
- 1997-03-14 WO PCT/FR1997/000469 patent/WO1997033466A1/fr not_active Application Discontinuation
- 1997-03-14 CA CA 2221028 patent/CA2221028A1/fr not_active Withdrawn
- 1997-03-14 AU AU21658/97A patent/AU2165897A/en not_active Abandoned
- 1997-03-14 JP JP9532343A patent/JPH11512623A/ja active Pending
- 1997-03-14 EP EP97914408A patent/EP0825811A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0825811A1 (fr) | 1998-03-04 |
| CA2221028A1 (fr) | 1997-09-18 |
| FR2745974B1 (fr) | 1998-04-17 |
| AU2165897A (en) | 1997-10-01 |
| WO1997033466A1 (fr) | 1997-09-18 |
| FR2745974A1 (fr) | 1997-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shafit-Zagardo et al. | The role of TAM family receptors and ligands in the nervous system: from development to pathobiology | |
| Simard et al. | Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia | |
| Rezaie et al. | Colonisation of the developing human brain and spinal cord by microglia: a review | |
| Miller et al. | Experimental autoimmune encephalomyelitis in the mouse | |
| Kloss et al. | Effect of lipopolysaccharide on the morphology and integrin immunoreactivity of ramified microglia in the mouse brain and in cell culture | |
| Fabriek et al. | CD163‐positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation | |
| Hickey et al. | Graft-vs.-host disease elicits expression of class I and class II histocompatibility antigens and the presence of scattered T lymphocytes in rat central nervous system. | |
| Ruuls et al. | Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats | |
| Griffin et al. | Macrophage responses and myelin clearance during Wallerian degeneration: relevance to immune-mediated demyelination | |
| Ha et al. | Critical role of the CXCL10/CXC chemokine receptor 3 axis in promoting leukocyte recruitment and neuronal injury during traumatic optic neuropathy induced by optic nerve crush | |
| KR20040084911A (ko) | 희소돌기아교세포 선조 세포를 이용한 선천적으로미엘린화되지 않은 전뇌의 미엘린화 | |
| Ivan et al. | Dwellers and trespassers: mononuclear phagocytes at the borders of the central nervous system | |
| Pedersen et al. | Enriched immune-environment of blood–brain barrier deficient areas of normal adult rats | |
| Thapa et al. | Emerging targets for modulation of immune response and inflammation in stroke | |
| US11567078B2 (en) | Blood cell biomarker for late onset Alzheimer's disease | |
| JPH08501535A (ja) | 疾患を治療するためのペプチド薬剤 | |
| US6576607B1 (en) | Methods using CNS neurite outgrowth modulators | |
| Sullivan et al. | Expression of rat target of the antiproliferative antibody (TAPA) in the developing brain | |
| Peng et al. | Distribution and temporal regulation of the immune response in the rat brain to intracerebroventricular injection of interferon-γ | |
| JPH11512623A (ja) | 多発性硬化症モデルとしての非−遺伝子修飾哺乳類 | |
| Barker et al. | Substance P and multiple sclerosis | |
| JP2005287430A (ja) | 脳梗塞疾患モデルマウス | |
| KR19990007893A (ko) | 중추신경계（ｃｎｓ） 축삭 성장 모듈레이터, 이를 구현 및 사용하는 조성물, 세포 및 방법 | |
| EP2908910A2 (fr) | Traitement d'une lésion cérébrale ou d'un traumatisme cérébral avec la protéine tsg-6 | |
| JP4503287B2 (ja) | 星状細胞及び星状細胞性腫瘍細胞の増殖を阻害する方法と、ニューロンの生存を高める方法、並びにその使用 |